Molecular basis for the effect of lipid lowering drugs on growth factors after de-endothelialization

Area of Science:

• Cardiovascular Research
• Pharmacology
• Molecular Biology

Background:

• Arterial restenosis is a significant complication following angioplasty.
• Understanding the molecular mechanisms involved is crucial for developing effective treatments.
• Lipid-lowering drugs are commonly used, but their specific effects on restenosis require further investigation.

Purpose of the Study:

• To investigate the mechanism by which lipid-lowering drugs inhibit arterial restenosis post-angioplasty.
• To evaluate the effect of simvastatin and gemfibrozil on growth factor expression in balloon-injured arteries.
• To assess the impact of these drugs on serum lipid levels and neointimal hyperplasia.

Main Methods:

• Rabbit aortae underwent balloon angioplasty to induce de-endothelialization.
• Expression of platelet-derived growth factor-B (PDGF-B), transforming growth factor beta-1 (TGF-beta-1), and basic fibroblast growth factor (bFGF) was analyzed.
• Serum total cholesterol (TC) and triglycerides (TG) were measured during treatment with simvastatin alone or in combination with gemfibrozil for six weeks.

Main Results:

• Simvastatin and gemfibrozil treatment inhibited PDGF-B release after de-endothelialization.
• A positive correlation was observed between TC and the intimal/medial ratio.
• While TGF-beta-1 increased in the neointima, bFGF mRNA levels showed no significant change in smooth muscle cells.

Conclusions:

• Lipid-lowering drugs, simvastatin and gemfibrozil, demonstrate effects beyond lipid reduction in preventing arterial restenosis.
• These drugs modulate the release of key growth factors, specifically PDGF-B and TGF-beta-1, in the neointima.
• The findings suggest a dual mechanism of action for these drugs in managing post-angioplasty complications.